NCT06475729View on ClinicalTrials.gov

A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

484

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

December 27, 2024

Study Completion Date

December 27, 2024

Conditions
Healthy
Interventions
DRUG

Citrate-Free Mirikizumab

Administered SC

Trial Locations (6)

32117

Fortrea Clinical Research Unit, Daytona Beach

53704

Fortrea Clinical Research Unit, Madison

65802

QPS Missouri, Springfield

75247

Fortrea Clinical Research Unit, Dallas

92801

CenExel ACT, Anaheim

33014-3616

Clinical Pharmacology of Miami, Miami

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT06475729 - A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants | Biotech Hunter | Biotech Hunter